TY - JOUR
T1 - Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality
AU - Mayes, Taryn L.
AU - Kennard, Betsy D.
AU - Killian, Michael
AU - Carmody, Thomas
AU - Grannemann, Bruce D.
AU - Rush, A. John
AU - Jha, Manish K.
AU - Hughes, Jennifer
AU - Emslie, Graham J.
AU - Trivedi, Madhukar H.
N1 - Funding Information:
Dr. Rush has received consulting fees from Brain Resource Ltd, Duke-NUS, Eli Lilly, Emmes Corp, Lundbeck A/S, Medavante Inc. Montana State University, National Institute of Drug Abuse, Santium, Inc., Stanford University, Takeda USA, the University of Colorado, University of Texas Southwestern Med Center; speaking fees from the University of California at San Diego, Hershey Penn State Medical Center, New York State Psychiatric Institute, the American Society for Clinical Psychopharmacology; royalties from Guilford Publications and the University of Texas Southwestern Medical Center; a travel grant from CINP; and research support from Duke -National University of Singapore. Through the University of Texas Southwestern Medical Center, he has a potential financial interest in the Inventory of Depressive Symptomatology and several variations of it. Graham Emslie receives research support from Duke University and Forest Research Institute, Inc.; and is a consultant for Assurex Health, Inc., INC Research, Inc., Lundbeck, Neuronetics Inc., Otsuka, and Texas Department of State Health Services. Dr. Trivedi receives research support from NIMH , NIDA, J&J, Janssen Research and Development LLC; has served as a consultant for Alkermes Inc., Allergan, Arcadia Pharmaceuticals Inc., AstraZeneca, Brintellix, BMS, Cerecor, Global Medical Education Inc., Health Research Associates, Lundbeck, Medscape, MSI Methylation Sciences Inc., Merck, Naurex Inc., Nestle Health Science – Pamlab Inc., One Carbon Therapeutics, Otsuka America Pharmaceuticals Inc., PamLab, Pfizer Inc., Roche, SHIRE Development, Takeda Pharmaceuticals Inc; and receives royalties from Janssen Research and Development LLC. Dr. Hughes receives royalties from Guildford Press. Ms. Mayes, Dr. Killian, Dr. Carmody, Mr. Grannemann, and Dr. Jha have no financial relationships to disclose.
Funding Information:
Dr. Rush has received consulting fees from Brain Resource Ltd, Duke-NUS, Eli Lilly, Emmes Corp, Lundbeck A/S, Medavante Inc. Montana State University, National Institute of Drug Abuse, Santium, Inc., Stanford University, Takeda USA, the University of Colorado, University of Texas Southwestern Med Center; speaking fees from the University of California at San Diego, Hershey Penn State Medical Center, New York State Psychiatric Institute, the American Society for Clinical Psychopharmacology; royalties from Guilford Publications and the University of Texas Southwestern Medical Center; a travel grant from CINP; and research support from Duke-National University of Singapore. Through the University of Texas Southwestern Medical Center, he has a potential financial interest in the Inventory of Depressive Symptomatology and several variations of it. Graham Emslie receives research support from Duke University and Forest Research Institute, Inc.; and is a consultant for Assurex Health, Inc., INC Research, Inc., Lundbeck, Neuronetics Inc., Otsuka, and Texas Department of State Health Services. Dr. Trivedi receives research support from NIMH, NIDA, J&J, Janssen Research and Development LLC; has served as a consultant for Alkermes Inc., Allergan, Arcadia Pharmaceuticals Inc., AstraZeneca, Brintellix, BMS, Cerecor, Global Medical Education Inc., Health Research Associates, Lundbeck, Medscape, MSI Methylation Sciences Inc., Merck, Naurex Inc., Nestle Health Science – Pamlab Inc., One Carbon Therapeutics, Otsuka America Pharmaceuticals Inc., PamLab, Pfizer Inc., Roche, SHIRE Development, Takeda Pharmaceuticals Inc; and receives royalties from Janssen Research and Development LLC. Dr. Hughes receives royalties from Guildford Press. Ms. Mayes, Dr. Killian, Dr. Carmody, Mr. Grannemann, and Dr. Jha have no financial relationships to disclose.
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Background: Several self-report rating scales have been developed to assess suicidal ideation, yet few examine other factors related to increased suicidal risk, and even fewer have been validated in both adolescents and adults. We evaluate the 14-item Concise Health Risk Tracking – Self Report (CHRT-SR), a measure previously validated in adults, in a sample of adolescents at risk for suicide. Method: Data are from a retrospective chart review of adolescents treated in an intensive outpatient program for youth with severe suicidality. Teens completed the CHRT-SR and Quick Inventory of Depressive Symptomatology – Adolescents (QIDS-A) at baseline and discharge. The CHRT-SR was evaluated to determine the factor validity, internal consistency, construct validity, and sensitivity to change. Results: Adolescents (n = 271) completed the CHRT-SR prior to treatment, and 231 completed the CHRT-SR at discharge. Three factors were identified with excellent model fit: Propensity, Impulsivity, and Suicidal Thoughts. Internal consistency reliability coefficients were good-to-excellent for the total score and all three factors at baseline (a = 0.774–0.915) and exit (a = 0.849–0.941). The total score and all three factors significantly correlated with overall depression severity and suicidal ideation as rated by teens and parent (p =.704–0.756, all p <.001). The CHRT-SR was sensitive to change, with moderate to large effect sizes (Cohen's d = 0.599–1.062). Limitations: Study limitations include generalizability, lack of a control group, and retrospective data from a sample of opportunity. Conclusions: The CHRT-SR is a reliable and valid measure for examining severity of suicidal thoughts and associated risk factors, and is sensitive to change following an intervention in adolescents.
AB - Background: Several self-report rating scales have been developed to assess suicidal ideation, yet few examine other factors related to increased suicidal risk, and even fewer have been validated in both adolescents and adults. We evaluate the 14-item Concise Health Risk Tracking – Self Report (CHRT-SR), a measure previously validated in adults, in a sample of adolescents at risk for suicide. Method: Data are from a retrospective chart review of adolescents treated in an intensive outpatient program for youth with severe suicidality. Teens completed the CHRT-SR and Quick Inventory of Depressive Symptomatology – Adolescents (QIDS-A) at baseline and discharge. The CHRT-SR was evaluated to determine the factor validity, internal consistency, construct validity, and sensitivity to change. Results: Adolescents (n = 271) completed the CHRT-SR prior to treatment, and 231 completed the CHRT-SR at discharge. Three factors were identified with excellent model fit: Propensity, Impulsivity, and Suicidal Thoughts. Internal consistency reliability coefficients were good-to-excellent for the total score and all three factors at baseline (a = 0.774–0.915) and exit (a = 0.849–0.941). The total score and all three factors significantly correlated with overall depression severity and suicidal ideation as rated by teens and parent (p =.704–0.756, all p <.001). The CHRT-SR was sensitive to change, with moderate to large effect sizes (Cohen's d = 0.599–1.062). Limitations: Study limitations include generalizability, lack of a control group, and retrospective data from a sample of opportunity. Conclusions: The CHRT-SR is a reliable and valid measure for examining severity of suicidal thoughts and associated risk factors, and is sensitive to change following an intervention in adolescents.
KW - Adolescent
KW - Assessment
KW - Psychometrics
KW - Rating scale
KW - Suicidal behavior
KW - Suicidal ideation
UR - http://www.scopus.com/inward/record.url?scp=85045217140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045217140&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2018.03.007
DO - 10.1016/j.jad.2018.03.007
M3 - Review article
C2 - 29649710
AN - SCOPUS:85045217140
SN - 0165-0327
VL - 235
SP - 45
EP - 51
JO - Journal of affective disorders
JF - Journal of affective disorders
ER -